572 related articles for article (PubMed ID: 18559409)
1. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
2. Commentary on 'designing phase II studies in cancer with time-to-event endpoints'.
Case D; Morgan T
Clin Trials; 2008; 5(3):222-3; discussion 223-4. PubMed ID: 18559410
[No Abstract] [Full Text] [Related]
3. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
4. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
5. Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint.
Kovalchik S; Mietlowski W
Contemp Clin Trials; 2011 Jan; 32(1):99-107. PubMed ID: 20920605
[TBL] [Abstract][Full Text] [Related]
6. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
7. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
8. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
Sposto R; Gaynon PS
Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
[TBL] [Abstract][Full Text] [Related]
9. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
10. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
Mazumdar M; Fazzari M; Panageas KS
Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
12. Alternate endpoints for screening phase II studies.
Dhani N; Tu D; Sargent DJ; Seymour L; Moore MJ
Clin Cancer Res; 2009 Mar; 15(6):1873-82. PubMed ID: 19276273
[TBL] [Abstract][Full Text] [Related]
13. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
14. Bivariate sequential designs for phase II trials.
Conaway MR; Petroni GR
Biometrics; 1995 Jun; 51(2):656-64. PubMed ID: 7662852
[TBL] [Abstract][Full Text] [Related]
15. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
16. Single-arm Phase II cancer survival trial designs.
Wu J
J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
[TBL] [Abstract][Full Text] [Related]
17. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
Healy BC; Ikle D; Macklin EA; Cutter G
Mult Scler; 2010 Jul; 16(7):840-7. PubMed ID: 20530124
[TBL] [Abstract][Full Text] [Related]
18. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
19. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
[TBL] [Abstract][Full Text] [Related]
20. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
